Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma

Summary

This study is a randomized, double-blinded assessment of biologic efficacy of AdcuCD40L. The individuals enrolled in this study will be individuals with biopsy proven resectable esophageal carcinoma. The dose of the AdcuCD40L vector (administered endoscopically directly to the tumor) will be the highest tolerable dose (most likely 10\^11 particle units) determined from Weill-IRB protocol #0011004683 dose escalation study.

Timeline

Start

2011-07

Primary completion

2011-07

Completion

2011-07

Outcome

Outcome not reported

Stopped (Business): “No funding available.”

Drugs

Indications